<DOC>
	<DOC>NCT00259064</DOC>
	<brief_summary>The purpose of the study is to determine if the addition of Iressa to Best Supportive Care treatment will increase the progression free survival of chemo-na√Øve, poor performance status patients, with stage IIIB or IV NSCLC.</brief_summary>
	<brief_title>Iressa v BSC (Best Supportive Care) in First Line NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically or cytologically confirmed NSCLC NSCLC locally advanced (Stage IIIB) or metastatic (stage IV) disease, not amenable to curative surgery or radiotherapy Not suitable for chemotherapy WHO Performance status 2 or 3 Newly diagnosed CNS mets Less than 4 weeks since completion of radiotherapy or persistence of any radiotherapy related toxicity Other coexisting malignancies ALT/AST greater than 5 x upper limit of normal ANC less than 1.0 x 109/L or platelets less than 100 x 109/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>